Agreement on Patent Litigation Between Axsome Therapeutics and Sandoz
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company focused on innovative therapies for central nervous system disorders, has come to an agreement with Sandoz Inc. to resolve the ongoing patent litigation concerning its product Sunosi (solriamfetol). This litigation was taking place in the United States District Court for the District of New Jersey and stemmed from Sandoz's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic version of Sunosi. With Sandoz's withdrawal of the ANDA, the litigation has now been dismissed without prejudice.
Overview of Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is committed to creating and providing groundbreaking therapies for central nervous system (CNS) disorders that currently have limited treatment options. The company aims to develop therapeutic solutions with unique mechanisms of action to reshape the treatment landscape for these conditions. Axsome is dedicated to advancing products that significantly improve patient lives and offer new alternatives for healthcare providers.
Commitment to CNS Research and Development
Innovative Therapeutic Approaches
Through thorough research and development, Axsome Therapeutics is focused on meeting the unmet needs of patients dealing with CNS disorders. The company’s portfolio features promising candidates designed to enhance treatment outcomes and improve quality of life.
Alignment with Market Demands
Axsome’s strategic initiatives are carefully crafted to meet market needs, allowing the company to prioritize therapies that have a significant impact on patient populations. This patient-focused approach ensures that the development process is centered around delivering effective and safe treatment options.
Investor and Media Relations
For any inquiries, investors and media representatives can reach out to the contacts listed below:
Investor Contact
Mark Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
One World Trade Center, 22nd Floor
Tel: 212-332-3243
Email: mjacobson@axsome.com
Media Contact
Darren Opland
Director, Corporate Communications
Axsome Therapeutics, Inc.
One World Trade Center, 22nd Floor
Tel: 929-837-1065
Email: dopland@axsome.com
Frequently Asked Questions
What was the nature of the litigation between Axsome and Sandoz?
The litigation involved a patent dispute where Sandoz aimed to market a generic version of Axsome's product Sunosi.
Why was the patent litigation dismissed?
The litigation was dismissed after Sandoz withdrew its Abbreviated New Drug Application (ANDA).
What is Sunosi (solriamfetol) used for?
Sunosi is a medication developed by Axsome Therapeutics that is intended to treat certain sleep disorders, providing significant relief for patients seeking help with their symptoms.
What is Axsome Therapeutics' primary focus?
Axsome Therapeutics is dedicated to developing innovative treatments for central nervous system disorders, with the goal of enhancing patient quality of life through novel therapeutic solutions.
Who should be contacted for more information about Axsome Therapeutics?
For more information, interested individuals can reach out to Mark Jacobson or Darren Opland using the provided email addresses for investor and media inquiries, respectively.
